References

• Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: A systematic review and meta-analysis. Br J Dermatol. 2018;179(2):282-289. google scholar
• Cristina Diniz Silva A, Ben Fadhel S. Ethnicity versus climate: The impacts of genetics and environment on rosacea epidemiology and pathogenesis. Arch Clin Exp Dermatol. 2020;2(1):109. google scholar
• Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2017;26(8):659-667. google scholar
• Rodrigues-Braz D, Zhao M, Yesilirmak N, Aractingi S, Behar-Cohen F, Bourges JL. Cutaneous and ocular rosacea: Common and specific physiopathogenic mechanisms and study models. Mol Vis. 2021;27:323-353. google scholar
• Daou H, Paradiso M, Hennessy K, Seminario-Vidal L. Rosacea and the microbiome: A systematic review. Dermatol Ther (Heidelb). 2021;11(1). doi:10.1007/s13555-020-00460-1 google scholar
• Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69(4):570-577. google scholar
• Chen C, Wang P, Zhang L, et al. Exploring the pathogenesis and mechanism-targeted treatments of rosacea: Previous understanding and updates. Biomedicines. 2023;11(8):2153. doi:10.3390/biomedicines11082153 google scholar
• Zhang L, Wu WKK, Gallo RL, et al. Critical role of antimicrobial peptide cathelicidin for controlling Helicobacter pylori survival and infection. J Immunol. 2016;196(4):1799-1809. google scholar
• Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. In: J Investig Dermatol Symp Proc. 2011;15:2-11. doi:10.1038/jidsymp.2011.7 google scholar
• Rainer BM, Kang S, Chien AL. Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2017;9(1):e1361574. doi:10.1080/19381980.2017.1361574 google scholar
• Gonzalez-Hinojosa D, Jaime-Villalonga A, Aguilar-Montes G, Lammoglia-Ordiales L. Demodex and rosacea: Is there a relationship? Indian J Ophthalmol. 2018;66(1):36-38. google scholar
• van Zuuren EJ, Arents BWM, van der Linden MMD, Vermeulen S, Fedorowicz Z, Tan J. Rosacea: New concepts in classification and treatment. Am J Clin Dermatol. 2021;22(4):457-465. google scholar
• Chang ALS, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015;135(6):1548-1555. google scholar
• Woo Y, Lim J, Cho D, Park H. Rosacea: Molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016;17(9):1562. doi:10.3390/ijms17091562 google scholar
• Cribier B. Rosacea under the microscope: Characteristic histological findings. J Eur Acad. Dermatol Venereol. 2013;27(11):1336-1343. google scholar
• Rosina P, Zamperetti MR, Giovannini A, Chieregato C, Girolomoni G. Videocapillaroscopic alterations in erythematotelangiectatic rosacea. J Am Acad Dermatol. 2006;54(1):100-104. google scholar
• Smith JR, Lanier VB, Braziel RM, Falkenhagen KM, White C, Rosenbaum JT. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol. 2007;91(2):226-229. google scholar
• Kumar V. Going, Toll-like receptors in skin inflammation and inflammatory diseases. Excli J. 2021;20:52-79. google scholar
• Portou MJ, Baker D, Abraham D, Tsui J. The innate immune system, toll-like receptors and dermal wound healing: A review. Vascul Pharmacol. 2015;71:31-36. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20(1):197-216. google scholar
• Kim JY, Kim YJ, Lim BJ, Sohn HJ, Shin D, Oh SH. Increased expression of cathelicidin by direct activation of protease-activated receptor 2: Possible implications on the pathogenesis of rosacea. Yonsei Med J. 2014;55(6):1648-1655. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15(1):12-15. google scholar
• Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Human CAP18: A novel antimicrobial lipopolysaccharide-binding protein. Infect Immun. 1995;63(4):1291-1297. google scholar
• Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA. 1995;92(1):195-199. google scholar
• Park BW, Ha JM, Cho EB, et al. A study on vitamin d and cathelicidin status in patients with rosacea: Serum level and tissue expression. Ann Dermatol. 2018;30(2):136-142. google scholar
• Meyer-Hoffert U. Reddish, scaly, and itchy: How proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp (Warsz). 2009;57(5):345-354. google scholar
• Fleischer AB. Inflammation in rosacea and acne: Implications for patient care. J Drugs Dermatol. 2011;10(6):614-620. google scholar
• Two AM, Del Rosso JQ.. Kallikrein 5-mediated inflammation in rosacea: Clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. J Clin Aesthet Dermatol. 2014;7(1):20-25. google scholar
• Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980. google scholar
• Hikmawati D, Fakih TM, Sutedja E, Dwiyana RF, atik N, Ramadhan DSF. Pharmacophore-guided virtual screening and dynamic simulation of Kallikrein-5 inhibitor: Discovery of potential molecules for rosacea therapy. Inform Med Unlocked. 2022;28. doi:10.1016/j.imu.2022.100844 google scholar
• Li J, Yuan X, Tang Y, et al. Hydroxychloroquine is a novel therapeutic approach for rosacea. Int Immunopharmacol. 2020;79:106178. doi:10.1016/ j.intimp.2019.106178 google scholar
• Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017;31(11):1775-1791. google scholar
• Amir Ali A, Vender R, Vender R. The Role of IL-17 in papulopustular rosacea and future directions. J Cutan Med Surg. 2019;23(6):635-641. google scholar
• Drago F, De Col E, Agnoletti AF, et al. The role of small intestinal bacterial overgrowth in rosacea: A 3-year follow-up. J Am Acad Dermatol. 2016;75(3):e113-e115. doi:10.1016/j.jaad.2016.01.059 google scholar
• Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: Clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759-764. google scholar
• Rubinchik E, Dugourd D, Algara T, Pasetka C, Friedland HD. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents. 2009;34(5):457-461. google scholar
• Salem DAB, El-shazly A, Nabih N, El-Bayoumy Y, Saleh S. Evaluation of the efficacy of oral ivermeotin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. Int J Infect Dis. 2013;17(5):e343-e347. doi:10.1016/j.ijid.2012.11.022 google scholar
• Gerber PA, Buhren BA, Steinhoff M, Homey B. Rosacea: The cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011;15(1):40-47. google scholar
• Asai Y, Tan J, Baibergenova A, et al. Canadian Clinical Practice Guidelines for Rosacea. J Cutan Med Surg. 2016;20(5):432-445. google scholar
• Del Rosso JQ, Tanghetti E, Webster G, Stein Gold L, Thiboutot D, Gallo RL. Update on the management of rosacea from the American Acne & Rosacea Society (AARS). J Clin Aesthet Dermatol. 2020;13(6 Suppl):S17-S24. google scholar
• Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82(6):1501-1510. google scholar
• Chen L, Tsai TF. The role of p-blockers in dermatological treatment: A review. J Eur Acad Dermatol Venereol. 2018;32(3):363-371. google scholar
• Al Mokadem SM, Ibrahim ASM, El Sayed AM. Efficacy of topical timolol 0.5% in the treatment of acne and rosacea: A multicentric study. J Clin Aesthet Dermatol. 2020;13(3):22-27. google scholar
• Layton AM. Pharmacologic treatments for rosacea. Clin Dermatol. 2017;35(2):207-212. google scholar
• Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: Results from a prospective randomized clinical trial. J Clin Oncol. 2005;23(28):6919-6930. google scholar
• Wagner KD, Berard R, Stein MB, et al. A Multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004;61(11):1153. doi:10.1001/ archpsyc.61.11.1153 google scholar
• Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol. 2005;53(5):881-884. google scholar
• Park J, Mun J, Song M, et al. Propranolol, doxycycline and combination therapy for the treatment of rosacea. J Dermatol. 2015;42(1):64-69. google scholar
• Zhou L, Zuo Z, Chow MSS. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45(12):1345-1359. google scholar
• Xu J, Wei K, Zhang G, et al. Ethnopharmacology, phytochemistry, and pharmacology of Chinese Salvia species: A review. J Ethnopharmacol. 2018;225:18-30. google scholar
• Su CY, Ming QL, Rahman K, Han T, Qin LP. Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology. Chin J Nat Med. 2015;13(3):163-182. google scholar
• Li X, Wang Z. Chemical composition, antimicrobial and antioxidant activities of the essential oil in leaves of Salvia miltiorrhiza Bunge. J Essent Oil Res. 2009;21(5):476-480. google scholar
• da Silva JKR, Figueiredo PLB, Byler KG, Setzer WN. Essential oils as antiviral agents. Potential of essential oils to treat sars-cov-2 infection: An in-silico investigation. Int J Mol Sci. 2020;21(10). doi:10.3390/ijms21103426 google scholar
• Wang J, Xu J, Gong X, Yang M, Zhang C, Li M. Biosynthesis, chemistry, and pharmacology of polyphenols from Chinese Salvia species: A review. Molecules. 2019;24(1):155. doi:10.3390/molecules24010155 google scholar
• Du G, Song J, Du L, et al. Chemical and pharmacological research on the polyphenol acids isolated from Danshen: A review of salvianolic acids. Adv Pharmacol. 2020:1-41. doi:10.1016/bs.apha.2019.12.004 google scholar
• Shanfa L. Compendium of plant genomes. In: Shanfa L, ed. The Salvia miltiorrhiza Genome. Vol 1. Springer Cham; 2019:XVI-192. doi:https://doi.org/10. 1007/978-3-030-24716-4 google scholar
• Wang X, Yang Y, Liu X, Gao X. Pharmacological properties of tanshinones, the natural products from Salvia miltiorrhiza. Adv Pharmacol. 2020;87:43-70. doi:10.1016/bs.apha.2019.10.001 google scholar
• Steinhoff M, Bergstresser PR. Pathophysiology of rosacea: Introduction. J Investig Dermatol. Symp Proc. 2011;15(1):1. doi:10.1038/jidsymp.2011.3 google scholar
• Wilkin JK. Rosacea. Arch Dermatol. 1994;130(3):359. doi:10.1001/archderm.1994.01690030091015 google scholar
• Jung I, Kim H, Moon S, Lee H, Kim B. Overview of Salvia miltiorrhiza as a potential therapeutic agent for various diseases: An update on efficacy and mechanisms of action. Antioxidants. 2020;9(9):857. doi:10.3390/antiox9090857 google scholar
• Liddle J, Beneton V, Benson M, et al. A potent and selective kallikrein-5 inhibitor delivers high pharmacological activity in skin from patients with Netherton syndrome. J Investig Dermatol. 2021;141(9):2272-2279. google scholar
• Walker AL, Bingham RP, Edgar EV, et al. Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton Syndrome. Bioorg Med Chem Lett. 2019;29(12):1454-1458. google scholar
• White GV, Edgar EV, Holmes DS, et al. Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome. Bioorg Med Chem Lett. 2019;29(6):821-825. google scholar
• Guan L, Yang H, Cai Y, et al, ADMET-score - A comprehensive scoring function for evaluation of chemical drug-likeness. Medchemcomm. 2019;10(1):148-157. google scholar

Citations